News for Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics (KYMR) has scheduled a video webcast for Friday, May 9, 2025. During the event, the company will present its financial outcomes for the firs

Summary Kymera Therapeutics Inc (KYMR), a clinical-stage biopharmaceutical company specializing in oral small molecule degrader medicines for immunological dise

**media[604241]**

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kymera Therapeutics (KYMR) has appointed Noah Goodman as Chief Business Officer. Goodman brings extensive experience in biotech business development and mer

On April 9, 2025, Kymera Therapeutics Inc (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Noah Goodman, M.B.A., as Chief Busine

Revenue: $7.4 million, all from Sanofi collaboration.R&D Expenses: $71.8 million, including $6.8 million in non-cash stock-based compensation.Adjusted Cash R&D

Exploring Kymera Therapeutics Inc's innovative approach to treating untreatable diseases through targeted protein degradation.Assessing the financial health an

Feb 27, 2025 / 01:30PM GMTOperator Good day everyone. My name is Megan and I will be your conference operator today. At this time, I would like to welcome you t

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsJustine Koenigsberg - Vice...

The following slide deck was published by Kymera Therapeutics, Inc.

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -15.79% and 43.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $7.4 million for Q4 2024, below the estimated $11.82 million.Net Loss: $70.8 million for Q4 2024, a significant increase from $14.4 million in Q4 2023

**media[552090]**

Kymera Therapeutics Inc (KYMR), a clinical-stage biopharmaceutical company, has released its financial results for the fourth quarter and full year ending Decem

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients ex

**media[545450]**

Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of KYMR stock now.

**media[544704]**